pLENTI6.3/AR-GC-E2325 Citations (7)

Originally described in: Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Oyan AM, Kalland K BMC Cancer. 2016 Jul 4;16:377. doi: 10.1186/s12885-016-2453-4. PubMed Journal

---

Articles Citing pLENTI6.3/AR-GC-E2325

Articles
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer. O'Connell TJ, Dadafarin S, Jones M, Rodriguez T, Gupta A, Shin E, Moscatello A, Iacob C, Islam H, Tiwari RK, Geliebter J. Front Cell Dev Biol. 2021 Aug 6;9:663130. doi: 10.3389/fcell.2021.663130. eCollection 2021. PubMed
Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer. Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. Sci Immunol. 2022 Jul;7(73):eabq2630. doi: 10.1126/sciimmunol.abq2630. Epub 2022 Jul 1. PubMed
Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model. Kido T, Lau YC. Oncogenesis. 2023 Feb 6;12(1):4. doi: 10.1038/s41389-023-00449-3. PubMed
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance. Alegre-Marti A, Jimenez-Panizo A, Martinez-Tebar A, Poulard C, Peralta-Moreno MN, Abella M, Anton R, Chinas M, Eckhard U, Piulats JM, Rojas AM, Fernandez-Recio J, Rubio-Martinez J, Le Romancer M, Aytes A, Fuentes-Prior P, Estebanez-Perpina E. Sci Adv. 2023 Mar 17;9(11):eade2175. doi: 10.1126/sciadv.ade2175. Epub 2023 Mar 15. PubMed
AR activates YAP/TAZ differentially in prostate cancer. Salem O, Jia S, Qian BZ, Hansen CG. Life Sci Alliance. 2023 Jun 29;6(9):e202201620. doi: 10.26508/lsa.202201620. Print 2023 Sep. PubMed
Androgens contribute to sex bias of autoimmunity in mice by T cell-intrinsic regulation of Ptpn22 phosphatase expression. Lee J, Yurkovetskiy LA, Reiman D, Frommer L, Strong Z, Chang A, Kahaly GJ, Khan AA, Chervonsky AV. Nat Commun. 2024 Sep 3;15(1):7688. doi: 10.1038/s41467-024-51869-7. PubMed
A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma. Fukui T, Okasho K, Okuno Y, Fujiwara M, Hikami K, Fukunaga A, Sunada T, Kita Y, Sumiyoshi T, Goto T, Saito R, Ogawa O, Kobayashi T, Akamatsu S. Cancer Med. 2025 Mar;14(5):e70047. doi: 10.1002/cam4.70047. PubMed

If you have published an article using this material, please email us at to have your article added to this page.